These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 19572232)
1. Small intestinal neuroendocrine tumors: prognostic factors and survival. Bergestuen DS; Aabakken L; Holm K; Vatn M; Thiis-Evensen E Scand J Gastroenterol; 2009; 44(9):1084-91. PubMed ID: 19572232 [TBL] [Abstract][Full Text] [Related]
2. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors. Boyar Cetinkaya R; Vatn M; Aabakken L; Bergestuen DS; Thiis-Evensen E Scand J Gastroenterol; 2014 Jun; 49(6):734-41. PubMed ID: 24679166 [TBL] [Abstract][Full Text] [Related]
3. A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival. Modlin IM; Gustafsson BI; Pavel M; Svejda B; Lawrence B; Kidd M Neuroendocrinology; 2010; 92(3):143-57. PubMed ID: 20733279 [TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Panzuto F; Nasoni S; Falconi M; Corleto VD; Capurso G; Cassetta S; Di Fonzo M; Tornatore V; Milione M; Angeletti S; Cattaruzza MS; Ziparo V; Bordi C; Pederzoli P; Delle Fave G Endocr Relat Cancer; 2005 Dec; 12(4):1083-92. PubMed ID: 16322345 [TBL] [Abstract][Full Text] [Related]
5. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Arnold R; Wilke A; Rinke A; Mayer C; Kann PH; Klose KJ; Scherag A; Hahmann M; Müller HH; Barth P Clin Gastroenterol Hepatol; 2008 Jul; 6(7):820-7. PubMed ID: 18547872 [TBL] [Abstract][Full Text] [Related]
6. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Strosberg J; Gardner N; Kvols L Neuroendocrinology; 2009; 89(4):471-6. PubMed ID: 19174605 [TBL] [Abstract][Full Text] [Related]
7. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. Rorstad O J Surg Oncol; 2005 Mar; 89(3):151-60. PubMed ID: 15719376 [TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE). Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576 [TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Pape UF; Berndt U; Müller-Nordhorn J; Böhmig M; Roll S; Koch M; Willich SN; Wiedenmann B Endocr Relat Cancer; 2008 Dec; 15(4):1083-97. PubMed ID: 18603570 [TBL] [Abstract][Full Text] [Related]
10. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors. Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995 [TBL] [Abstract][Full Text] [Related]
11. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Modlin IM; Champaneria MC; Chan AK; Kidd M Am J Gastroenterol; 2007 Jul; 102(7):1464-73. PubMed ID: 17391319 [TBL] [Abstract][Full Text] [Related]
12. The significance of CD44 expression in gastrointestinal neuroendocrine tumors. Lai CH; Shan YS; Sy ED; Hsieh YH; Tsai HW; Lee JC; Lin PW Hepatogastroenterology; 2005; 52(64):1071-6. PubMed ID: 16001632 [TBL] [Abstract][Full Text] [Related]
13. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Strosberg J; Nasir A; Coppola D; Wick M; Kvols L Hum Pathol; 2009 Sep; 40(9):1262-8. PubMed ID: 19368957 [TBL] [Abstract][Full Text] [Related]
14. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors. Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071 [TBL] [Abstract][Full Text] [Related]
15. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors. Modlin IM; Gustafsson BI; Drozdov I; Nadler B; Pfragner R; Kidd M Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963 [TBL] [Abstract][Full Text] [Related]
16. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374 [TBL] [Abstract][Full Text] [Related]
18. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Durante C; Boukheris H; Dromain C; Duvillard P; Leboulleux S; Elias D; de Baere T; Malka D; Lumbroso J; Guigay J; Schlumberger M; Ducreux M; Baudin E Endocr Relat Cancer; 2009 Jun; 16(2):585-97. PubMed ID: 19240182 [TBL] [Abstract][Full Text] [Related]
19. The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors. Lim E; Yap YK; De Stavola BL; Nicholson AG; Goldstraw P J Thorac Cardiovasc Surg; 2005 Oct; 130(4):969-72. PubMed ID: 16214506 [TBL] [Abstract][Full Text] [Related]
20. Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors. Curran T; Tulin-Silver S; Patel K; Ward S; Schneiderman M; Harpaz N; Schwartz M; Itzkowitz S; Warner RR; Kim MK Pancreas; 2011 Nov; 40(8):1253-7. PubMed ID: 21975435 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]